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Abstract
Background: Rectal infection with Chlamydia trachomatis is one of the most common bacterial sexually transmissible
infections among men who have sex with men (MSM) with diagnosis rates continuing to rise. Current treatment
guidelines recommend either azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days. However,
there are increasing concerns about treatment failure with azithromycin. We are conducting the first randomised
controlled trial (RCT) to compare treatment efficacy of azithromycin versus doxycycline for the treatment of rectal
chlamydia in MSM.
Methods/Design: The Rectal Treatment Study will recruit 700 MSM attending Australian sexual health clinics for the
treatment of rectal chlamydia. Participants will be asked to provide rectal swabs and will be randomised to either
azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days. Participants will be asked to complete
questionnaires about adverse drug reactions, sexual behaviour and drug adherence via short message service and
online survey. The primary outcome is the treatment efficacy as determined by a negative chlamydia nucleic acid
amplification test at 4 weeks post treatment. Secondary outcomes will utilise whole genome sequencing and mRNA
assay to differentiate between treatment failure, reinfection or false positive results.
Discussion: Rectal chlamydia is an increasing public health concern as use of pre-exposure prophylaxis against HIV
becomes commonplace. Optimal, evidence-based treatment is critical to halting ongoing transmission. This study will
provide the first RCT evidence comparing azithromycin and doxycycline for the treatment of rectal chlamydia. The
results of this trial will establish which treatment is more efficacious and inform international management guidelines.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12614001125617.
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Background
Anogenital Chlamydia trachomatis is the most commonly
diagnosed bacterial sexually transmissible infection (STI)
with an estimated 131 million new cases of among 15–49
year-olds worldwide in 2012 [1]. In countries that screen
both men and women for chlamydia, men account for ap-
proximately 40% of all new diagnoses [2–5]. Although these
data do not differentiate between urethral, pharyngeal or
rectal infection, available prevalence data among men who
have sex with men (MSM) report that rectal infection (5.6–
8.2%) is more common than urethral infection (2.1–5.4%)
[6–9], with the L2b serovariant indicated in Lymphogranu-
loma venereum (LGV) [10].
The widespread uptake of biomedical prevention such
as pre-exposure prophylaxis (PrEP) for HIV is likely to
lead to further increases in rectal chlamydia among
MSM [11]. Data from PrEP implementation studies in
the US and Australia are showing an increased incidence
of rectal STIs among MSM using PrEP [12–14]. The
NSW PrEP Demonstration Project found an annual
incidence of rectal chlamydia of 67.5% [14] with rates
of between 33 and 48% observed in similar projects
in the US [12, 13].
Current STI treatment guidelines recommend either
azithromycin 1 g single dose or doxycycline 100 mg
twice daily for 7 days for the treatment of rectal chla-
mydia [15–18]. However, there has been increasing con-
cern about the effectiveness of azithromycin for rectal
chlamydia with observational studies reporting failure
rates of up to 22% [19–22].
In response to these concerns, guidelines in several
countries are now recommending that rectal chlamydia
infections are treated with 7 days doxycycline [15, 16,
18], rather than 1 g azithromycin as first line. However,
there are potential problems adhering to a 7-day course
of doxycycline which can lead to an increased risk of
treatment failure [22].
A recent meta-analysis reported a treatment efficacy of
approximately 83% for azithromycin 1 g single dose com-
pared with 99% for doxycycline 100 mg twice daily for
7 days for rectal chlamydia infection [23]. However, this
analysis was based on observational data only with no avail-
able evidence from randomized control trials (RCTs). Given
that STI rates may continue to increase among MSM and
that there is increasing concern about rectal chlamydia
among women [24–26], treatment for rectal chlamydia
must be proven to be efficacious. A double-blind RCT is
urgently needed to rigorously estimate the difference in effi-
cacy between azithromycin and doxycycline. The results
will inform treatment guidelines worldwide.
Research aim and hypothesis
The primary aim is to estimate the efficacy of azithromy-
cin 1 g single dose for the treatment of rectal chlamydia
among MSM and compare it to that of doxycycline
100 mg, twice daily for 7 days.
We hypothesize that doxycycline (100 mg, twice daily
for 7 days) will be superior to azithromycin (1 g single
dose) for the treatment of rectal chlamydia.
Methods/Design
Study design and setting
This is a double-blind (clinicians and patients) RCT.
Given our primary outcome is treatment efficacy, our
trial is double blind to minimize bias that could arise as
a result of the different dosing regimens of the two drugs
(7 days vs single dose). For example: i) it is possible that
taking a 7-day course of daily doxycycline rather than a
single dose of azithromycin may deter people from re-
suming sexual activity while taking treatment, thereby
reducing their risk of a new infection, and; ii) partici-
pants could be less adherent to a 7-day regimen which
could impact efficacy [27, 28]. The trial will be con-
ducted within sexual health clinics in Victoria and New
South Wales in Australia and in accordance with the
Declaration of Helsinki. The trial was approved by the
Alfred Hospital Ethics Committee (373/15).
(NOTE: hereafter, “azithromycin” refers to azithromycin
1 g single dose and “doxycycline” refers to doxycycline
(100 mg, twice daily for 7 days).
Duration of study




Men will be eligible for inclusion if they report male
to male sexual contact in the past 12 months, are
aged ≥16 years and test positive for rectal chlamydia
using a nucleic acid amplification test (NAAT). They
must have adequate English and comprehension skills
to give informed consent.
HIV positive MSM will be eligible to participate as
there is no evidence that treatment efficacy differs by
HIV status. A recent RCT comparing azithromycin with
doxycycline for the treatment of chlamydia urethritis
found no difference in efficacy between HIV positive
and negative men [29]. International STI management
guidelines do not differentiate by HIV status for chla-
mydia treatment [15–18, 30].
Exclusion criteria
Men will be excluded if they: i) report use of antibiotics
for other purposes in the last 2 weeks; ii) have a known
contraindication to the use of azithromycin or doxycyc-
line including allergy; iii) present with symptomatic
proctitis. Because MSM will be recruited at clinical
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services, it will not be possible to genotype their infec-
tions to detect LGV at recruitment. LGV genotyping will
take place at the conclusion of the trial. Men who are
randomised and subsequently found to have asymptom-
atic LGV based on genotyping at the conclusion of the
trial, estimated to be <6% of the trial population [31] will
be excluded from our analysis as LGV requires more
prolonged doxycycline treatment for cure [32]. The sam-
ple size will account for this – see Sample Size.
Recruitment
MSM who are diagnosed with asymptomatic rectal
chlamydia at participating clinics will be approached by
a research nurse and invited to take part in the
trial (Fig. 1). The nurse will explain the trial, assess
eligibility and obtain consent. Eligible men will be enrolled
and randomly assigned to either azithromycin or
doxycycline. Participants will provide three self-collected
rectal swab samples and complete a brief question-
naire. Self-collected swabs have been shown to have
similar test performance compared with clinician-
collected swabs for chlamydia testing [33]. Once randomly
allocated to a treatment group, the nurse will then directly
observe participants taking the first dose of treatment
(with food).
Intervention
Participants will be randomly allocated to one of the
following treatment groups:
Azithromycin: Participants will receive 1 g of active
azithromycin (500 mg tablets × 2), plus 13 placebo doxy-
cycline tablets, identical in appearance to the active
azithromycin. Participants will be required to take the
two azithromycin tablets under observation at time of
recruitment and then advised to take a single placebo
tablet morning and night for the next 7 days;
Doxycycline: Participants will receive 14 active doxy-
cycline tablets (100 mg), plus one placebo azithromycin
tablet, all identical in appearance to active azithromycin.
Participants will be required to take one active doxycyc-
line and one placebo azithromycin tablets under obser-
vation at time of recruitment and then advised to take a
single active doxycycline tablet morning and night for
the next 7 days.
Participants will be advised to take the drugs with food
to minimize gastrointestinal side effects and to minimize
sun exposure or use sun screen to reduce the risk of
photosensitivity.
Randomization and sequence generation, allocation
concealment and blinding
A computer-generated randomization sequence will be
created by an independent statistician. Blinded therapy
will be prepared by an independent organization and
labelled with individual kit numbers according to
randomization. Study drugs will be packaged into indi-
vidually numbered kits stored by independent site phar-
macists. All tablets will be identical in appearance and
feel, and all medications will be packaged identically to
maintain blinding. Participants, physicians, nurses, trial
statistician and all other trial staff will be masked to
treatment group. The effectiveness of blinding will be
tested at completion of the trial when participants will
be asked to indicate which treatment they thought they
received (including being able to indicate “don’t know”).
The side-effect profiles of the drugs will have negli-
gible impact on blinding. They have been widely used
for chlamydia for decades at the dosages we will be
using. Their side-effect profiles are well established and
similar including minor gastrointestinal upset (nausea,
stomach cramps, diarrhoea, vomiting, gastric reflux)
[34]. Photosensitivity may occur for doxycycline but is
more common with longer or higher dosages [35]. Rash
is a rare side effect for each drug, occurring in 0.1–1% of
cases [34]. Our packaging will clearly state sunscreen
should be used and exposure to sun minimalized,
thereby reducing the risk of photosensitivity. We exam-
ined the side-effect data from treatment trials for ureth-
ral/cervical chlamydia and found that among 17 trials,
there was no difference in side-effects (24.0% for azithro-
mycin vs 23.0% for doxycycline, p = 0.45) [36].
Outcomes
Primary outcome
Treatment efficacy measured as microbial cure defined
as a negative chlamydia NAAT test result performed on
a self-collected rectal swab at week 4.
Secondary outcomes
We will further differentiate between treatment failure
and chlamydia re-infection using whole genome sequen-
cing (WGS) and mRNA tests (see below for further de-
tail) for any cases testing chlamydia NAAT positive on a
rectal swab at week 4. Using the algorithm (Fig. 2), our
secondary outcomes will be classified as: i) microbial
cure based on a negative chlamydia NAAT test result at
week 4; ii) false positive diagnosis if chlamydia NAAT
positive at week 4, but no evidence of mRNA detected
[37]; iii) new infection if infected with a different
organism (based on sequencing results) OR if the same
organism and the participant reports unprotected anal
receptive sex between tests; iv) chlamydia treatment fail-
ure if infected with exactly the same organism and no
reports of unprotected sex between recruitment and
week 4 follow up. [NOTE: This algorithm assumes that
if a man has a repeat infection with exactly the same
organism confirmed by sequencing and reports unpro-
tected sex, he will be classified as having a new infection
Lau et al. BMC Infectious Diseases  (2017) 17:35 Page 3 of 9
Fig. 2 Algorithm for defining repeat infection. PCR = polymerase chain reaction, WGS =whole genome sequencing, mRNA=messenger ribonucleic acid
Fig. 1 Outline of trial schema. Follow up at 4 weeks post recruitment
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rather than treatment failure. This is because unprotected
sex is one of the greatest risk factors for chlamydia [38].
We acknowledge that this classification will not be 100%
accurate, but this level of discrimination has never been
previously undertaken in any study of chlamydia treat-
ment efficacy. Our RCT design should ensure that cases
classified as a new infection or a false positive diagnosis
will be evenly distributed between trial arms, minimising
any differential measurement bias.
Follow up
Men will be required to provide specimens and behav-
ioral data until the conclusion of the trial at 4 weeks
(Table 1). Men will be asked to attend the clinic at
4 weeks for a final study visit. At the 4-week visit, the re-
search nurse will administer a final paper questionnaire
and additional rectal swabs will be self-collected for
WGS and mRNA assay.
Specimen collection
MSM will be asked to provide self-collected rectal
swabs.
Specimen processing and extraction
All swabs will be sent to the Molecular Microbiology
Laboratory, Royal Women’s Hospital for processing and
testing. Swabs collected for routine NAAT and WGS will
be rotated in 400 μL phosphate buffered saline for 30 s.
Swabs collected for mRNA will be rotated in 1 ml of
RNAlater (Lifetechnologies) preservative solution (Ambion,
Austin, TX, USA) and stored at -80 °C until further testing
is required. An aliquot of 200 μl will be extracted by the au-
tomated MagNA Pure 96 isolation and purification system
(Roche Diagnostics, Mannheim, Germany) using the DNA
and Viral NA Small Volume isolation kit. Following nucleic
acid isolation, all samples will be initially assessed for DNA
and RNA adequacy with a quantitative PCR for a 260 bp
fragment of the human beta-globin gene [39] and 226 bp
fragment of U1A transcript. [40] Chlamydia testing will be
done by the Cobas 4800 CT/NG assay (Roche Applied Sci-
ence) as per the manufacturer’s instructions.
Genotype (strain) determination
Identification of each chlamydia strain including LGV
will be determined by qPCR assays using serovar-
specific probes as we have described previously [41].
Whole genome sequencing (WGS)
Samples from MSM who test chlamydia NAAT positive
at week 4 with the same genotype as their baseline sam-
ple will undergo WGS to identify the specific strain for
each specimen and identify whether the organisms are
identical. We will use a direct DNA probe capture
method to capture chlamydial DNA directly from the
swab sample and sequence the entire genome [42, 43].
Others have used OmpA genotyping or multi-locus se-
quence typing to characterise genovar [44], but these
techniques are considerably less discriminatory than
Table 1 Trial timeline
Recruitment Day 1 Days 2-6 Day 7 Day 14 Day 21 Follow up Day 28
Recruitment
Pre-eligibility assessment X
Informed consent obtained X
Enrollment and randomisation X
Dosage under supervision X
Data collection Format
Baseline questionnaire Paper X
Adverse drug reactions SMS/Online X
Sexual behaviour SMS/Online X X X
Other medications SMS/Online X X X
Drug adherence SMS/Online X
Follow up questionnaire Paper X
Specimen collection Number
Self-collected swabs 3 X
Self-collected swabs 2 X
Test of cure swab 1 X
SMS short message service. 3 swabs collected at recuitment: 1 for whole genome sequencing if required, one for mRNA and 1 for culture. 3 swabs collected at
follow up: 1 for whole genome sequencing if required, 1 for mRNA and one for test of cure
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WGS. Our trial will be the first to use WGS to help dif-
ferentiate between new infection and treatment failure.
mRNA
To ensure only actively transcribed nucleic acid is
evaluated (as a marker of active, viable infection), extracted
nucleic acid will be treated with 10U/μl DNase (Roche
Diagnostic) for 10 min at 37 °C, followed by inactivation of
DNase. Resultant RNA will undergo one-step reverse
transcription and qPCR using the method by Storm et al.
[37]. Any case that has mRNA detected will be classified as
a true positive. Cases in which mRNA is not detected will
be classified as false positive cases. Our trial will be the first
to use mRNA assays to identify false positive cases.
Data collection (Table 1)
Questionnaire at recruitment
Participants will complete a paper-based survey at re-
cruitment covering demographics and sexual health, in-
cluding symptoms and sexual behaviour data. This will
include: number of partners; types of sexual activity (in-
cluding insertive/receptive anal sex); use of intra-rectal
devices (eg sex toys); condom use; type of lubrication
used and details about douching pre/post sex and types
of fluids used for douching. The questions on douching,
water based lubricants and intra-rectal devices have been
included because they may reduce the antibiotic concen-
trations in the rectal mucosa due to epithelial damage
[45–48]. HIV status, use of pre-exposure prophylaxis for
HIV or anti-retroviral therapy, and most recent viral
load will be obtained from their medical record.
Weekly data collection
Participants will be asked to respond to a weekly short
message service (SMS) that collects (via online link)
whether they had: any receptive anal sex in the last
week; sex with any new sexual partners; sex without a
condom in the last week; used any douching and/or
intra-rectal devices; any anogenital symptoms; any chla-
mydia testing elsewhere; taken any further antibiotics.
Side effect reporting
During the first week, participants will also be asked daily
via SMS whether they had any diarrhoea or vomiting that
could impact on their levels of antibiotic absorption.
At the 4-week follow up
Participants will complete another paper-based ques-
tionnaire that collects information regarding symptoms
and sexual behaviour data, diagnosis of any STIs during
follow up (which will be validated against their medical
record) and what treatment they believe they received.
We will also collect information about any recent HIV
viral loads and/or CD4 counts.
Drug adherence monitoring
Participants will be asked to complete a questionnaire
about drug adherence at the end of week 1. They will also
be asked to return the pill bottle for a pill count as proxy
measure of drug adherence. A previous study comparing
self-report with measured adherence using the Medication
Event Monitoring System, found 83% concordance
between self-report and measured adherence for taking
11–14 doses among 206 men and women [28].
Adverse events reporting
We do not expect any severe adverse events as these drugs
have been widely used for decades and their side-effect
profiles are well-established. Nevertheless, we will record
adverse events which will be coded using the Medical
Dictionary for Regulatory Activities (MedDRA). The per-
centage of patients with treatment-emergent adverse
events will be tabulated by system organ class and severity
of these events with particular focus on gastrointestinal
events together with severity of these events [49].
Sample size
Our hypothesis is that azithromycin efficacy will be less
than that of doxycycline. On the basis of our meta-
analysis, we assume that the microbial cure among the
doxycycline arm at 4 weeks will be 98% compared to azi-
thromycin at 93%. We will recruit 700 men in total (350
in each group) which, allowing for a very conservative
14% loss to follow up (based on our experience with
similar trials of MSM) [50] and a further loss of 6% due
to a LGV diagnosis at the end of the trial, will give us an
effective sample size of 560. This sample size will allow
us to detect a 5% difference between doxycycline and
azithromycin microbial cure at 4 weeks with 80% power
and a 6% difference with 90% power. If microbial cure is
96% among those treated with doxycycline at week 4,
then we will have 80% power to detect a 6% difference
and 90% power to detect a 7% difference (Table 2).
Analysis
We will compare the proportion with microbial cure at
4 weeks between arms using the Chi square test, and
95% confidence intervals for the difference between
Table 2 Sample size calculation
Doxycycline cure 98% cure 96% cure
Power 80% 90% 80% 90%
Difference to detecta
% 538 720 762 1018
6% 412 552 560 756
7% 332 442 444 592
aAssumes azithromycin microbial cure will be 5–7% lower. Sample size
calculation assumes 5% significance
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proportions reported. While randomisation should en-
sure balance of baseline characteristics, if there are
meaningful differences in baseline characteristics includ-
ing sexual behaviour, a multivariable logistic regression
analysis will be undertaken to adjust for these factors.
Primary analysis
Our primary analysis will be a modified intention to
treat analysis (m-ITT) including only those who com-
menced randomised therapy at recruitment (at least one
dose) and those who provided a rectal specimen for
chlamydia testing at week 4.
Secondary analysis
We will undertake two per protocol analyses in which
participants who took less than 10 doses of their allo-
cated treatment [28] or vomited within 1 h of any dose
will be excluded: i) an analysis of the primary outcome
of the microbial cure, and; ii) an analysis of the second-
ary outcome of microbial cure in which cases classified
as new infection or a false diagnosis are grouped with
microbial cure to create a binary variable for the analysis
(microbial cure [including new infection and false posi-
tive cases] vs treatment failure).
Trial status
The trial has been registered on the Australian and New
Zealand Clinical Trials Registry (ACTRN12614001125617).
The trial commenced recruitment in August 2016 and is
due to be completed by August 2019.
Discussion
Given rectal chlamydia is highly prevalent among MSM
and is likely to increase, it is vital that the most effica-
cious treatment is used. Currently azithromycin, which
meta-analysis suggests might fail in 17% of cases [23], is
continuing to be widely used. This will be the first RCT
to compare azithromycin and doxycycline for rectal
chlamydia and will establish whether doxycycline is
more efficacious than azithromycin.
Currently, there are no pharmacokinetic data available
for the action of azithromycin in rectal mucosa and a
complex interplay of pharmacological and immuno-
logical factors means that azithromycin may be less
effective for rectal compared with urethral/cervical in-
fections [51]. Azithromycin is delivered to the site of in-
fection by phagocytic cells released during the immune
response to infection [52] whereas doxycycline is highly
lipid soluble and rapidly absorbed into the tissues [53].
Data from both human studies [54] and mice models
[55] suggest that chlamydia down-regulates the immune
response in the gastrointestinal tract, and may therefore
reduce the number of phagocytic cells available to de-
liver the azithromycin. Other mouse studies have shown
that gastrointestinal chlamydiae are less susceptible to
clearance by azithromycin than genital species [55].
Therefore, it is biologically plausible that a reduced local
immune response in the rectum may attenuate azithro-
mycin efficacy.
We have limited the trial to MSM because most rectal
chlamydia is diagnosed among MSM and regular screen-
ing for rectal STIs is recommended only for this popula-
tion [16]. Nevertheless, our results will have implications
for women in whom rectal chlamydia can be diagnosed
[56]. The biology of rectal infection is likely to be similar
between men and women with similar rectal organism
loads reported for both men and women [57]. In addition,
Gratrix et al. found no significant difference in rectal treat-
ment efficacy between men and women [58]. As such, we
believe our results will be generalizable to women.
A repeat positive chlamydia test at follow up does not
necessarily indicate treatment failure; it could be a re-
infection or a false positive result. A strength of this trial
is that we can take advantage of the latest technology to
more accurately discriminate between treatment failure
and re-infection or false positive result. We will use
WGS to differentiate between new infection and treat-
ment failure. WGS is the most discriminatory tool avail-
able as it can identify conclusively whether the specific
strain at follow up is different from that at recruitment
thereby indicating a new infection. Previously, studies
have used OmpA genotyping or multi-locus sequence
typing (MLST) to characterise the genovar [44], but
these techniques are considerably less discriminatory
than WGS. We will use mRNA tests to identify false
positive cases. Standard chlamydia tests detect chlamydia
nucleic acid which includes both viable and non-viable
(dead) organisms. When antibiotic treatment kills chla-
mydia, it can take 3 weeks to clear the nucleic acid from
the genital tract [59], so any NAAT conducted during this
time may detect non-viable organism only and be a false
positive. Chlamydial mRNA assays use a quantitative real-
time chlamydia molecular test (see p7) and will quantita-
tively measure mRNA transcription of omp2 (omcB) outer
membrane protein in chlamydia as an expression of viable
organisms (active infection) [37]. In addition, we will col-
lect comprehensive sexual practice data to identify men at
risk of re-infection using SMS.
This trial must be done to ensure STI management
guidelines internationally are evidence-based and recom-
mend the most efficacious treatment for rectal chlamydia
so that ongoing transmission is minimised.
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